U.K. Pharma Stocks Could Outperform European Peers If U.K. Gets Lighter Tariffs -- Market Talk

Dow Jones2025-04-02

1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com)

(END) Dow Jones Newswires

April 02, 2025 09:19 ET (13:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524249648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524249648","market":"hk","top_or_hot":-1,"title":"U.K. Pharma Stocks Could Outperform European Peers If U.K. Gets Lighter Tariffs -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 09:19 ET (13:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.K. Pharma Stocks Could Outperform European Peers If U.K. Gets Lighter Tariffs -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.K. Pharma Stocks Could Outperform European Peers If U.K. Gets Lighter Tariffs -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-02 21:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 09:19 ET (13:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNN","symbol_name":"Smith & Nephew PLC ADS","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524249648","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524249648","pubTimestamp":1743599940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SNN":"Smith & Nephew PLC ADS","AZN":"阿斯利康","GSK":"葛兰素史克"},"translate_title":"如果英国降低关税，英国制药股的表现可能会优于欧洲同行——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNN":0.9,"GSK":0.9,"AZN":0.9},"content_text":"1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 09:19 ET (13:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524249648","isCrawlerRequest":true}